Cargando…

P1421: BIMODAL TARGETING OF CYTOKINE RECEPTOR-LIKE FACTOR 2 (CRLF2) WITH JAK INHIBITION AND CHIMERIC ANTIGEN RECEPTOR T CELL IMMUNOTHERAPY IN DOWN SYNDROME ACUTE LYMPHOBLASTIC LEUKEMIA

Detalles Bibliográficos
Autores principales:	Bagashev, A., Loftus, J., Niswander, L., Ross, S., Falkenstein, C. D., Junco, J., Rabin, K. R., Fry, T., Tasian, S. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428976/ http://dx.doi.org/10.1097/01.HS9.0000848544.25019.34

Ejemplares similares

Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2022)

P344: ONCOGENESIS OF CRLF2 OVEREXPRESSION AND EFFECT OF A NOVEL JAK2 INHIBITOR IN CRLF2 OVEREXPRESSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Gu, Yan, et al.
Publicado: (2023)

Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia
por: Loftus, Joseph P., et al.
Publicado: (2020)

High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement
por: Ge, Zheng, et al.
Publicado: (2016)

Characterisation of the genomic landscape of CRLF2‐rearranged acute lymphoblastic leukemia
por: Russell, Lisa J., et al.
Publicado: (2017)

Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia
por: Zhang, Qi, et al.
Publicado: (2018)

Multiparametric flow cytometry directing the evaluation of CRLF2 rearrangements and JAK2 status in pediatric B cell precursor acute lymphoblastic leukemia
por: Noronha, Elda Pereira, et al.
Publicado: (2023)

Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia
por: Mittelman, Steven D., et al.
Publicado: (2021)

BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia
por: Tsuzuki, Shinobu, et al.
Publicado: (2022)

TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia
por: Alkashgari, Hossam R., et al.
Publicado: (2022)

Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia
por: Vesely, C, et al.
Publicado: (2017)

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
por: Qin, Haiying, et al.
Publicado: (2021)

Clinical characterization and prognosis of T cell acute lymphoblastic leukemia with high CRLF2 gene expression in children
por: Wang, Mingmin, et al.
Publicado: (2019)

The cytokine receptor CRLF3 is a human neuroprotective EV-3 (Epo) receptor
por: Knorr, Debbra Y., et al.
Publicado: (2023)

Cytokine Receptor-Like Factor 1 (CRLF1) Protects against 6-Hydroxydopamine Toxicity Independent of the gp130/JAK Signaling Pathway
por: Looyenga, Brendan D., et al.
Publicado: (2013)

The Insect Ortholog of the Human Orphan Cytokine Receptor CRLF3 Is a Neuroprotective Erythropoietin Receptor
por: Hahn, Nina, et al.
Publicado: (2017)

CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition
por: Meyer, Lauren K., et al.
Publicado: (2019)

Correction: Cytokine Receptor-Like Factor 1 (CRLF1) Protects against 6-Hydroxydopamine Toxicity Independent of the gp130/JAK Signaling Pathway
por: Looyenga, Brendan D., et al.
Publicado: (2014)

CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia
por: Palmi, Chiara, et al.
Publicado: (2016)

The enigmatic role(s) of P2RY8-CRLF2
por: Panzer-Grümayer, Renate, et al.
Publicado: (2017)

The rare translocation t(14;21)(q11;q22) detected in a Moroccan patient with T-cell acute lymphoblastic leukemia
por: Chebihi, Z. Takki, et al.
Publicado: (2018)

Cytokine Receptor-Like Factor 3 (CRLF3) Contributes to Early Zebrafish Hematopoiesis
por: Taznin, Tarannum, et al.
Publicado: (2022)

The Orphan Cytokine Receptor CRLF3 Emerged With the Origin of the Nervous System and Is a Neuroprotective Erythropoietin Receptor in Locusts
por: Hahn, Nina, et al.
Publicado: (2019)

SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia
por: Sarno, Jolanda, et al.
Publicado: (2018)

Locust Hemolymph Conveys Erythropoietin-Like Cytoprotection via Activation of the Cytokine Receptor CRLF3
por: Knorr, Debbra Y., et al.
Publicado: (2021)

Potential efficacy and prognosis of silencing the CRLF2-mediated AKT/mTOR pathway in pediatric acute B-cell lymphoblastic leukemia
por: Jiang, Min, et al.
Publicado: (2019)

IKZF1 deletions associate with CRLF2 overexpression leading to a poor prognosis in B-cell precursor acute lymphoblastic leukaemia
por: Maciel, Ana Luiza Tardem, et al.
Publicado: (2021)

Gain of chromosome 21 increases the propensity for P2RY8: :CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression
por: Page, Elyse C., et al.
Publicado: (2023)

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2021)

CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways
por: Moreno Lorenzana, Dafné, et al.
Publicado: (2021)

Poor outcome of pediatric B-cell acute lymphoblastic leukemia associated with high level of CRLF2 gene expression in distinct molecular subtypes
por: Lin, Danna, et al.
Publicado: (2023)

Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes
por: Shah, Shrenik K., et al.
Publicado: (2015)

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Tomuleasa, Ciprian, et al.
Publicado: (2018)

Single cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia
por: Potter, N, et al.
Publicado: (2018)

Draft Genome Sequence of New Vancomycin-Resistant Enterococcus faecium Sequence Type 1421
por: Leong, Kelvin W. C., et al.
Publicado: (2018)

1421. Microbiology and Resistance of Diabetic Foot Osteomyelitis in a Teaching Hospital in Santiago, Chile
por: Valenzuela, Pablo Tomas, et al.
Publicado: (2019)

CRLF1 and CLCF1 in Development, Health and Disease
por: Crisponi, Laura, et al.
Publicado: (2022)

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
por: Kim, Sang-Kyu, et al.
Publicado: (2018)

Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia
por: Grover, Punita, et al.
Publicado: (2022)

Successful therapy of chimeric antigen receptor T cells for isolated extramedullary acute lymphoblastic leukemia
por: Li, Xiangqun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ohaa5v47dr3tidq0fca1c2aee2